

Exhibit 1

This Exhibit is hereby incorporated into the New Product Master Services Agreement, dated February 1, 2008, as amended, by and between **Abbott Laboratories Inc.** ("Client") and **Walgreen Co.** ("Walgreens").

SERVICES:

Using content provided by Client and as further described herein, Walgreens will prepare two (2) Product Information Reports ("PI Reports") for the following pharmaceutical product and will disseminate such PI Reports to its pharmacists:

Product Brand Name: Vicodin®
Generic name: hydrocodone bitartrate / acetaminophen
Manufacturer: Abbott
Communication: Vicodin product information

In addition to disseminating the PI Reports to its pharmacists, Walgreens shall post each PI Report once on RxNet, the weekly electronic pharmacy update bulletin distributed to Walgreens' stores. Each PI Report shall include a disclosure that Client is providing financial support for such report. Walgreens shall not modify any PI Report without Abbott's prior written consent.

The parties acknowledge that the PI Reports are an effective way to educate Walgreens' pharmacists on new, revised or innovative pharmaceutical products. PI Reports may also be utilized as a tool to assist pharmacists in making sound, clinical decisions when dispensing these medications.

TOTAL COST:

The cost to prepare and disseminate the PI Reports (including development and maintenance of the PI Reports on RxNet) shall be Fifteen Thousand Dollars (\$15,000.00) per PI Report, for a total of Thirty Thousand Dollars (\$30,000.00) for both reports. Client shall pay each amount of Fifteen Thousand Dollars (\$15,000.00) after Client's receipt of documentation of completion of the services described herein.

The parties agree that the total amounts payable hereunder constitute fair market value for the services provided hereunder and have not been determined in any manner that takes into account the past, present, or future volume or value of referrals (e.g., purchases, prescriptions) generated between the parties.

TIME LINE FOR DEVELOPMENT/IMPLEMENTATION:

- Walgreens shall commence development of the PI Reports for Vicodin upon the parties' execution of this Exhibit and the provision of the input materials for the PI Reports. It is anticipated that Client shall provide Walgreens with the input materials for the first PI Report by June 1, 2012 and for the second PI Report by September 1, 2012.
- Immediately upon finalizing a PI Report (including making any revisions requested by Client), Walgreens shall distribute the PI Report as described above.
- Each PI Report is subject to final approval by Client. Walgreens shall not modify any PI Report without Client's prior written consent.

ADVERSE EVENT REPORTING

Walgreens shall report adverse events related to Vicodin to Medwatch and Client's Global Pharmacovigilance Department by telephone (1-800-633-9110 or 1-847-938-0601) within one (1) business day of Walgreens becoming aware of an adverse event.



IN WITNESS WHEREOF, the parties hereto have caused this Exhibit to be executed by their duly authorized representatives as of this date as shown below.

CLIENT

WALGREENS CO

By _____

By _____

Title _____

Title _____

Date _____

Date _____